Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

Gabriel N. Hortobagyi, Salomon M. Stemmer, Howard A. Burris, Yoon-Sim Yap, Gabe S. Sonke, Lowell Hart, Mario Campone, Katarina Petrakova, Eric P. Winer, Wolfgang Janni, Pierfranco Conte, David A. Cameron, Fabrice André, Carlos L. Arteaga, Juan P. Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O’Shaughnessy

Open source

DOI: 10.1056/nejmoa2114663
Published: 2022-03-10
Container: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2114663,
  title = {Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer},
  author = {Gabriel N. Hortobagyi and Salomon M. Stemmer and Howard A. Burris and Yoon-Sim Yap and Gabe S. Sonke and Lowell Hart and Mario Campone and Katarina Petrakova and Eric P. Winer and Wolfgang Janni and Pierfranco Conte and David A. Cameron and Fabrice André and Carlos L. Arteaga and Juan P. Zarate and Arunava Chakravartty and Tetiana Taran and Fabienne Le Gac and Paolo Serra and Joyce O’Shaughnessy},
  year = {2022},
  journal = {New England Journal of Medicine},
  doi = {10.1056/nejmoa2114663},
  url = {https://doi.org/10.1056/nejmoa2114663}
}

RIS

TY  - JOUR
TI  - Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
AU  - Gabriel N. Hortobagyi
AU  - Salomon M. Stemmer
AU  - Howard A. Burris
AU  - Yoon-Sim Yap
AU  - Gabe S. Sonke
AU  - Lowell Hart
AU  - Mario Campone
AU  - Katarina Petrakova
AU  - Eric P. Winer
AU  - Wolfgang Janni
AU  - Pierfranco Conte
AU  - David A. Cameron
AU  - Fabrice André
AU  - Carlos L. Arteaga
AU  - Juan P. Zarate
AU  - Arunava Chakravartty
AU  - Tetiana Taran
AU  - Fabienne Le Gac
AU  - Paolo Serra
AU  - Joyce O’Shaughnessy
PY  - 2022
JO  - New England Journal of Medicine
DO  - 10.1056/nejmoa2114663
UR  - https://doi.org/10.1056/nejmoa2114663
ER  -

APA

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y., Sonke, G. S., Hart, L., Campone, M., Petrakova, K., Winer, E. P., Janni, W., Conte, P., Cameron, D. A., André, F., Arteaga, C. L., Zarate, J. P., Chakravartty, A., Taran, T., Gac, F. L., Serra, P., & O’Shaughnessy, J. (2022). Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2114663

Source records

crossref · retrieved 2026-11-10T19:22:42.964Z